We have 8 of 109 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Summary Background The cardiovascular-kidney-liver-metabolic (CKLM) framework represents the multi-organ interplay of systemic metabolic disorders that drive the global burden of cardiovascular diseases (CVD). Methods This study is a descriptive epidemiological analysis of the Global Burden of Disease Study 2023 that e...
Abstract Aims Cancer therapy-related cardiac dysfunction (CTRCD) is a prevalent complication with adverse clinical implications. Guidelines have emphasized the need for reliable baseline risk prediction to guide prevention strategies. While machine learning (ML) has shown promise in cardiovascular medicine, the readine...
Lipoprotein(a) [Lp(a)] is a genetically determined, apolipoprotein B-containing lipoprotein that contributes to cardiovascular risk through atherogenic, proinflammatory, and potentially antifibrinolytic mechanisms. Genetic, epidemiological, and mechanistic evidence supports a causal role for elevated Lp(a) in atheroscl...
Pre-existing CVD at cancer diagnosis has increased substantially over 2 decades and is projected to affect nearly half of patients by 2050, which underscores the need for the expansion of cardio-oncology services.
This study showed an increased lifetime cancer risk and mortality in men compared with women, which was mediated by comorbid CVD.
The burden of pre-existing CVD at cancer diagnosis has increased substantially over the past two decades in the UK and is projected to rise further, highlighting the growing need for integrated prevention strategies and cardio-oncology services to address increasing multimorbidity in patients with cancer.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
